Physician
Presbyterian Healthcare Services
Presbyterian Healthcare Services was paid $240.24M by Medicaid between Jan 2018 and Dec 2024, across 542 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 28% of everything it billed.
33Billing provider infoPRESBYTERIAN HEALTHCARE SERVICES
ALBUQUERQUE, NM 87109
ALBUQUERQUE, NM 87109
33aNPI1104802354assigned 12/20/2005
33bProvider typeSurgery Physician
28Total paid$240.24M
24GClaims3,995,600
24DCodes billed542
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Surgery Physician providers in New Mexico
Rank by total paid#1 of 18
Median peer was paid$32K
This provider vs. median7,502×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 681,982 | $28.79M | |
| 2019 | 579,459 | $33.23M | |
| 2020 | 486,328 | $28.55M | |
| 2021 | 613,192 | $33.43M | |
| 2022 | 645,288 | $37.63M | |
| 2023 | 515,147 | $37.89M | |
| 2024incomplete | 474,204 | $40.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 28% | 792,008 | 762,069 | $66.15M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 469,940 | 457,274 | $29.86M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 96,720 | 96,301 | $13.31M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 3.6% | 81,458 | 76,661 | $8.76M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 3.0% | 16,458 | 6,771 | $7.23M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.0% | 70,543 | 66,044 | $7.20M |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 2.7% | 127,038 | 55,513 | $6.41M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.7% | 65,124 | 64,887 | $6.37M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.6% | 60,536 | 60,384 | $6.13M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.0% | 36,845 | 36,382 | $4.88M |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 1.8% | 56,744 | 23,865 | $4.38M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.7% | 41,516 | 41,441 | $4.19M |
530 more codes
| 99203 | Doctor's office visit, new patient (routine) | 1.6% | 42,462 | $3.79M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.5% | 28,717 | $3.50M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.1% | 26,968 | $2.72M |
| 90472 | Immunization administration, each additional vaccine (list separately) | 1.0% | 58,203 | $2.48M |
| 99239 | Hospital discharge day management, more than 30 minutes | 1.0% | 29,367 | $2.47M |
| J2357 | Injection, omalizumab, 5 mg | <1% | 1,200 | $2.29M |
| 99283 | Emergency room visit (moderate) | <1% | 39,679 | $2.27M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 29,931 | $2.08M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 40,437 | $1.99M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 53,333 | $1.97M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 92,035 | $1.85M |
| 90461 | <1% | 42,150 | $1.80M | |
| 99205 | Prolong outpt/office vis | <1% | 9,701 | $1.77M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 44,541 | $1.70M |
| 99223 | Prolong inpt eval add15 m | <1% | 12,001 | $1.62M |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 15,270 | $1.60M |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 217,199 | $1.54M |
| 90837 | Psychotherapy session, about an hour | <1% | 15,389 | $1.53M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13,085 | $1.52M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 14,894 | $1.51M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 71,099 | $1.51M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 24,032 | $1.51M |
| J0178 | Injection, aflibercept, 1 mg | <1% | 612 | $1.37M |
| 90791 | Psychiatric diagnostic evaluation | <1% | 11,478 | $1.33M |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 82,201 | $1.24M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 7,995 | $1.15M |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 7,766 | $1.04M |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 21,133 | $1.03M |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 14,127 | $965K |
| 64615 | <1% | 7,290 | $858K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 4,652 | $844K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 15,165 | $842K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 46,588 | $807K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 5,002 | $694K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 9,721 | $677K |
| 99460 | <1% | 7,223 | $635K | |
| J7326 | Hyaluronan or derivative, gel-one, for intra-articular injection, per dose | <1% | 488 | $631K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 3,195 | $543K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 36,095 | $539K |
| 99443 | <1% | 4,327 | $456K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 4,060 | $435K |
| 59025 | Fetal non-stress test | <1% | 13,583 | $419K |
| 93970 | <1% | 10,439 | $396K | |
| 93304 | <1% | 3,832 | $352K | |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 840 | $326K |
| 93971 | <1% | 13,351 | $322K | |
| 0001A | <1% | 9,477 | $320K | |
| 0002A | <1% | 8,518 | $305K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 297 | $304K |
| 88307 | <1% | 4,141 | $303K | |
| 93320 | <1% | 8,216 | $301K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 3,072 | $279K |
| 99607 | <1% | 16,761 | $263K | |
| 99606 | <1% | 17,362 | $251K | |
| 81025 | <1% | 28,759 | $234K | |
| 90473 | <1% | 11,037 | $225K | |
| 20610 | <1% | 5,005 | $214K | |
| 93325 | <1% | 14,048 | $206K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,952 | $181K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,117 | $181K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,943 | $181K |
| 95811 | <1% | 1,727 | $171K | |
| 81002 | <1% | 53,344 | $171K | |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | <1% | 91 | $170K |
| 87650 | <1% | 9,326 | $168K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,363 | $162K |
| 95806 | <1% | 3,102 | $161K | |
| 99472 | Subsequent inpatient pediatric critical care, per day, 2-5 years | <1% | 396 | $151K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,465 | $151K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,330 | $141K |
| 54150 | <1% | 1,603 | $141K | |
| 99254 | <1% | 873 | $136K | |
| 95813 | <1% | 1,513 | $133K | |
| 93000 | <1% | 8,781 | $131K | |
| 99381 | <1% | 745 | $129K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 569 | $127K |
| 87634 | <1% | 1,813 | $124K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,403 | $123K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 3,664 | $123K |
| 99442 | <1% | 1,501 | $122K | |
| 80053 | Comprehensive metabolic panel | <1% | 13,116 | $118K |
| 99201 | <1% | 3,104 | $118K | |
| 97802 | <1% | 1,940 | $117K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,162 | $110K |
| 99383 | <1% | 635 | $109K | |
| 87631 | <1% | 771 | $107K | |
| 43762 | <1% | 1,159 | $106K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,042 | $101K |
| J2778 | Injection, ranibizumab, 0.1 mg | <1% | 52 | $97K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 1,150 | $97K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,315 | $97K |
| 90686 | <1% | 57,658 | $94K | |
| 87632 | <1% | 454 | $92K | |
| 88342 | <1% | 2,688 | $83K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 274 | $80K |
| 93321 | <1% | 4,088 | $74K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 817 | $74K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,471 | $70K |
| 99253 | <1% | 669 | $69K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,299 | $68K |
| 95886 | <1% | 806 | $65K | |
| 97803 | <1% | 2,590 | $64K | |
| 93925 | <1% | 1,033 | $64K | |
| 95819 | <1% | 1,326 | $63K | |
| 99243 | <1% | 448 | $59K | |
| 99221 | <1% | 773 | $57K | |
| 0071A | <1% | 1,408 | $56K | |
| 11750 | <1% | 480 | $56K | |
| 95782 | <1% | 383 | $55K | |
| 0124A | <1% | 1,463 | $55K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,522 | $54K |
| 99384 | <1% | 303 | $52K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 523 | $50K |
| 84439 | <1% | 6,369 | $49K | |
| 87480 | <1% | 2,855 | $49K | |
| 87660 | <1% | 2,854 | $49K | |
| 87510 | <1% | 2,854 | $49K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,571 | $49K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,712 | $45K |
| 95251 | <1% | 1,545 | $45K | |
| 0072A | <1% | 1,099 | $44K | |
| 73630 | <1% | 2,016 | $42K | |
| 0011A | <1% | 1,115 | $41K | |
| 99245 | <1% | 180 | $41K | |
| J2777 | Injection, faricimab-svoa, 0.1 mg | <1% | 14 | $41K |
| 99462 | <1% | 1,068 | $40K | |
| 90785 | <1% | 3,855 | $40K | |
| 99441 | <1% | 845 | $38K | |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | <1% | 15 | $37K |
| 0012A | <1% | 957 | $37K | |
| 64405 | <1% | 444 | $36K | |
| 85027 | <1% | 6,609 | $36K | |
| 93296 | <1% | 2,233 | $33K | |
| 87505 | <1% | 285 | $33K | |
| 99477 | <1% | 102 | $33K | |
| 82728 | <1% | 2,934 | $32K | |
| 80074 | <1% | 728 | $31K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,851 | $31K |
| 95812 | <1% | 571 | $30K | |
| 94729 | <1% | 1,640 | $30K | |
| 94010 | <1% | 2,106 | $29K | |
| 86803 | <1% | 2,272 | $29K | |
| 93298 | <1% | 1,418 | $29K | |
| 93294 | <1% | 1,790 | $28K | |
| 99349 | <1% | 381 | $28K | |
| 93880 | <1% | 457 | $28K | |
| 94060 | <1% | 1,461 | $28K | |
| 94726 | <1% | 1,401 | $28K | |
| 87653 | <1% | 985 | $28K | |
| 0004A | <1% | 985 | $27K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 2,226 | $26K |
| 59510 | <1% | 14 | $26K | |
| 86780 | <1% | 2,199 | $26K | |
| 20550 | <1% | 543 | $25K | |
| 93926 | <1% | 658 | $25K | |
| 93922 | <1% | 681 | $25K | |
| 99255 | <1% | 108 | $25K | |
| 85060 | <1% | 1,349 | $24K | |
| 93295 | <1% | 708 | $23K | |
| 99152 | <1% | 645 | $23K | |
| 87522 | Neg quan hep c or qual rna | <1% | 563 | $23K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,192 | $23K |
| 83516 | <1% | 1,948 | $21K | |
| 0081A | <1% | 513 | $21K | |
| 76857 | <1% | 525 | $20K | |
| 82607 | <1% | 1,613 | $20K | |
| 0154A | <1% | 478 | $20K | |
| 88304 | <1% | 1,843 | $20K | |
| 0031A | <1% | 526 | $19K | |
| 0054A | <1% | 571 | $19K | |
| 87902 | <1% | 77 | $19K | |
| 86235 | <1% | 249 | $18K | |
| 92551 | <1% | 1,443 | $17K | |
| 87077 | <1% | 2,591 | $17K | |
| 90480 | <1% | 825 | $17K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,251 | $17K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 127 | $17K |
| 90715 | <1% | 3,148 | $17K | |
| 36556 | <1% | 172 | $17K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 908 | $16K |
| 87340 | <1% | 1,766 | $16K | |
| 84702 | <1% | 1,259 | $16K | |
| 64493 | <1% | 155 | $16K | |
| 83550 | <1% | 2,128 | $16K | |
| 83970 | <1% | 562 | $16K | |
| 80305 | <1% | 1,188 | $15K | |
| 87186 | <1% | 2,060 | $15K | |
| 0082A | <1% | 351 | $15K | |
| 86762 | <1% | 1,120 | $15K | |
| 82746 | <1% | 1,189 | $14K | |
| 43235 | <1% | 105 | $14K | |
| 86480 | <1% | 258 | $14K | |
| 99177 | <1% | 377 | $14K | |
| 97804 | <1% | 1,434 | $13K | |
| 0064A | <1% | 411 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,853 | $13K |
| 80061 | Lipid panel | <1% | 1,087 | $13K |
| 99382 | <1% | 79 | $13K | |
| 59514 | <1% | 39 | $12K | |
| 83540 | <1% | 2,193 | $12K | |
| 77080 | <1% | 1,604 | $12K | |
| 99385 | <1% | 75 | $12K | |
| 99188 | <1% | 590 | $12K | |
| 86038 | <1% | 1,095 | $11K | |
| 99605 | <1% | 1,056 | $11K | |
| 93990 | <1% | 560 | $11K | |
| 95816 | <1% | 247 | $11K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 19 | $11K |
| 99252 | <1% | 150 | $11K | |
| 84403 | <1% | 481 | $11K | |
| 0074A | <1% | 269 | $11K | |
| 20611 | <1% | 203 | $11K | |
| D1120 | Dental cleaning, child | <1% | 341 | $11K |
| 86003 | <1% | 164 | $11K | |
| 43760 | <1% | 104 | $11K | |
| 85610 | <1% | 3,302 | $10K | |
| 72114 | <1% | 323 | $10K | |
| 0134A | <1% | 326 | $10K | |
| 93975 | <1% | 130 | $10K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 12 | $10K |
| 94375 | <1% | 690 | $10K | |
| 86140 | <1% | 2,156 | $10K | |
| 99417 | Prolong home eval add 15m | <1% | 600 | $9K |
| 43775 | <1% | 156 | $9K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 50 | $9K |
| 99406 | <1% | 893 | $9K | |
| 93245 | <1% | 77 | $9K | |
| 86376 | <1% | 680 | $9K | |
| 82570 | <1% | 2,022 | $9K | |
| 0111A | <1% | 212 | $9K | |
| 82784 | <1% | 1,078 | $9K | |
| 99350 | Prolong home eval add 15m | <1% | 54 | $9K |
| 86850 | <1% | 1,188 | $8K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 170 | $8K |
| 82043 | <1% | 1,679 | $8K | |
| 77089 | <1% | 490 | $8K | |
| 81003 | <1% | 4,165 | $8K | |
| 99471 | <1% | 13 | $8K | |
| 99476 | <1% | 25 | $8K | |
| 0173A | <1% | 181 | $8K | |
| 47562 | <1% | 14 | $7K | |
| 96131 | <1% | 52 | $7K | |
| 90756 | <1% | 373 | $7K | |
| 99463 | <1% | 62 | $7K | |
| 73564 | <1% | 333 | $7K | |
| 98968 | <1% | 245 | $7K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 408 | $7K |
| 86787 | <1% | 649 | $7K | |
| 83001 | <1% | 440 | $7K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 41 | $7K |
| 96130 | <1% | 157 | $7K | |
| 31231 | <1% | 52 | $7K | |
| 84481 | <1% | 441 | $7K | |
| Q3014 | Telehealth originating site facility fee | <1% | 282 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 391 | $7K |
| 43273 | <1% | 72 | $7K | |
| 96367 | <1% | 300 | $7K | |
| 80076 | <1% | 955 | $7K | |
| 52000 | <1% | 73 | $7K | |
| 96161 | <1% | 1,623 | $7K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 79 | $6K |
| 95720 | <1% | 54 | $6K | |
| 87338 | <1% | 493 | $6K | |
| 70355 | <1% | 364 | $6K | |
| 84153 | <1% | 414 | $6K | |
| 0112A | <1% | 147 | $6K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 64 | $6K |
| 86800 | <1% | 407 | $6K | |
| 95910 | <1% | 41 | $6K | |
| 86160 | <1% | 507 | $6K | |
| 0013A | <1% | 169 | $6K | |
| 84270 | <1% | 304 | $6K | |
| 83655 | <1% | 517 | $6K | |
| 90670 | <1% | 32,035 | $6K | |
| 82670 | <1% | 232 | $6K | |
| 81001 | <1% | 2,101 | $6K | |
| 86706 | <1% | 579 | $6K | |
| 86704 | <1% | 508 | $5K | |
| 84146 | <1% | 334 | $5K | |
| 64635 | <1% | 27 | $5K | |
| 83002 | <1% | 328 | $5K | |
| 93458 | <1% | 29 | $5K | |
| 90656 | <1% | 4,291 | $5K | |
| 86200 | <1% | 462 | $5K | |
| 96127 | <1% | 655 | $5K | |
| 93015 | <1% | 98 | $5K | |
| 83525 | <1% | 441 | $5K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 37 | $5K |
| D1110 | Prophylaxis - adult | <1% | 116 | $5K |
| 85652 | <1% | 2,087 | $5K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 1,123 | $5K |
| 87529 | <1% | 145 | $5K | |
| 87799 | <1% | 121 | $5K | |
| 94660 | <1% | 85 | $5K | |
| 64494 | <1% | 84 | $5K | |
| 99451 | <1% | 157 | $5K | |
| 96417 | <1% | 65 | $5K | |
| D0274 | Bitewings - four radiographic images | <1% | 170 | $5K |
| 64495 | <1% | 80 | $5K | |
| 82274 | <1% | 336 | $5K | |
| 90651 | <1% | 12,675 | $5K | |
| 86431 | <1% | 909 | $5K | |
| 51798 | <1% | 422 | $4K | |
| 73130 | <1% | 230 | $4K | |
| 86147 | <1% | 69 | $4K | |
| 82951 | <1% | 385 | $4K | |
| 58300 | <1% | 24 | $4K | |
| 31575 | <1% | 37 | $4K | |
| 82565 | <1% | 903 | $4K | |
| 90620 | <1% | 769 | $4K | |
| 96380 | <1% | 194 | $4K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 60 | $4K |
| 0121A | <1% | 88 | $4K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 174 | $4K |
| 82378 | <1% | 223 | $4K | |
| 96137 | <1% | 85 | $4K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 102 | $3K |
| 69210 | <1% | 85 | $3K | |
| 11721 | <1% | 214 | $3K | |
| 83520 | <1% | 259 | $3K | |
| 83690 | <1% | 529 | $3K | |
| 82105 | <1% | 225 | $3K | |
| 0083A | <1% | 80 | $3K | |
| 86225 | <1% | 276 | $3K | |
| 82248 | <1% | 751 | $3K | |
| 87449 | <1% | 266 | $3K | |
| 82977 | <1% | 497 | $3K | |
| 99292 | <1% | 46 | $3K | |
| 86900 | <1% | 1,211 | $3K | |
| 86901 | <1% | 1,210 | $3K | |
| 87070 | <1% | 435 | $3K | |
| 84445 | <1% | 85 | $3K | |
| 86255 | <1% | 294 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 981 | $3K |
| 0164A | <1% | 75 | $3K | |
| 84520 | <1% | 879 | $3K | |
| 84480 | <1% | 244 | $3K | |
| 84305 | <1% | 161 | $3K | |
| 95909 | <1% | 26 | $3K | |
| 82247 | <1% | 647 | $3K | |
| 83880 | <1% | 92 | $3K | |
| 82533 | <1% | 205 | $3K | |
| 91321 | <1% | 17 | $3K | |
| 99219 | <1% | 37 | $3K | |
| 87075 | <1% | 326 | $3K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 29 | $3K |
| 83615 | <1% | 513 | $3K | |
| 99217 | <1% | 44 | $3K | |
| 20605 | <1% | 77 | $3K | |
| 85730 | <1% | 483 | $3K | |
| 84484 | <1% | 283 | $2K | |
| 86696 | <1% | 132 | $2K | |
| 95911 | <1% | 13 | $2K | |
| 43264 | <1% | 12 | $2K | |
| 20553 | <1% | 45 | $2K | |
| 90688 | <1% | 7,369 | $2K | |
| 84295 | <1% | 537 | $2K | |
| 83735 | <1% | 402 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 32 | $2K |
| 93297 | <1% | 197 | $2K | |
| 84550 | <1% | 582 | $2K | |
| 86708 | <1% | 214 | $2K | |
| 84132 | <1% | 553 | $2K | |
| 0053A | <1% | 64 | $2K | |
| 82950 | <1% | 568 | $2K | |
| 0151A | <1% | 52 | $2K | |
| 58301 | <1% | 13 | $2K | |
| 92511 | <1% | 27 | $2K | |
| 82550 | <1% | 397 | $2K | |
| 0051A | <1% | 54 | $2K | |
| 11982 | <1% | 12 | $2K | |
| 84165 | <1% | 236 | $2K | |
| 82947 | <1% | 605 | $2K | |
| 87328 | <1% | 186 | $2K | |
| 82435 | <1% | 516 | $2K | |
| 86039 | <1% | 211 | $2K | |
| 82024 | <1% | 52 | $2K | |
| 62323 | <1% | 12 | $2K | |
| 83721 | <1% | 215 | $2K | |
| 84460 | <1% | 408 | $2K | |
| 64490 | <1% | 24 | $2K | |
| 92201 | <1% | 164 | $2K | |
| 95885 | <1% | 50 | $2K | |
| 82150 | <1% | 289 | $2K | |
| 84450 | <1% | 395 | $2K | |
| 96160 | <1% | 435 | $2K | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 63 | $2K |
| 90750 | <1% | 13 | $2K | |
| 64636 | <1% | 12 | $2K | |
| 96101 | <1% | 84 | $2K | |
| 99480 | Subsequent intensive care, per day, low birth weight infant | <1% | 16 | $2K |
| 86695 | <1% | 132 | $2K | |
| 84432 | <1% | 111 | $2K | |
| 92557 | <1% | 48 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 285 | $2K |
| 87205 | <1% | 426 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 760 | $2K |
| 88141 | <1% | 76 | $2K | |
| 99220 | <1% | 19 | $1K | |
| 73610 | <1% | 80 | $1K | |
| 11720 | <1% | 133 | $1K | |
| 76827 | <1% | 14 | $1K | |
| 29540 | <1% | 61 | $1K | |
| 85390 | <1% | 64 | $1K | |
| J7318 | Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | <1% | 35 | $1K |
| 85379 | <1% | 162 | $1K | |
| 84144 | <1% | 58 | $1K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 180 | $1K |
| 86146 | <1% | 44 | $1K | |
| G0452 | Molecular pathology procedure; physician interpretation and report | <1% | 88 | $1K |
| 37253 | <1% | 13 | $1K | |
| 96136 | <1% | 83 | $1K | |
| 83883 | <1% | 110 | $1K | |
| 83993 | <1% | 56 | $1K | |
| 84156 | <1% | 381 | $1K | |
| 0052A | <1% | 29 | $1K | |
| 92567 | <1% | 65 | $1K | |
| 82103 | <1% | 103 | $1K | |
| 84100 | <1% | 245 | $1K | |
| 93241 | <1% | 12 | $1K | |
| 90474 | <1% | 50 | $1K | |
| 82390 | <1% | 118 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 77 | $993.83 |
| 73110 | <1% | 58 | $981.65 | |
| 93280 | <1% | 36 | $972.04 | |
| 90746 | <1% | 14 | $938.84 | |
| 91320 | <1% | 13 | $938.49 | |
| 93244 | <1% | 40 | $932.89 | |
| 87088 | <1% | 134 | $930.33 | |
| 64491 | <1% | 15 | $929.91 | |
| 64492 | <1% | 15 | $905.64 | |
| 91200 | <1% | 39 | $875.28 | |
| 37252 | <1% | 13 | $834.85 | |
| 0171A | <1% | 20 | $828.40 | |
| 93299 | <1% | 30 | $825.88 | |
| 46600 | <1% | 14 | $778.81 | |
| 92226 | <1% | 17 | $776.88 | |
| 0094A | <1% | 27 | $763.20 | |
| 86308 | <1% | 145 | $742.71 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 27 | $741.44 |
| 82040 | <1% | 156 | $741.02 | |
| 29405 | <1% | 12 | $735.46 | |
| 84703 | <1% | 105 | $734.95 | |
| 84436 | <1% | 94 | $719.06 | |
| D0120 | Dental checkup, returning patient | <1% | 31 | $690.68 |
| 85018 | <1% | 302 | $670.89 | |
| 98967 | <1% | 27 | $645.30 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 636 | $635.82 |
| 93018 | <1% | 55 | $620.93 | |
| 86256 | <1% | 75 | $618.97 | |
| 90674 | <1% | 1,021 | $607.64 | |
| 86060 | <1% | 86 | $601.37 | |
| 99418 | Prolong nursin fac eval 15m | <1% | 13 | $595.88 |
| 87324 | <1% | 44 | $559.17 | |
| 90685 | <1% | 2,772 | $531.73 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 35 | $474.44 |
| 85613 | <1% | 44 | $471.13 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $465.31 |
| 87081 | <1% | 96 | $450.94 | |
| 99347 | <1% | 12 | $447.67 | |
| G0270 | Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes | <1% | 86 | $435.71 |
| 99459 | <1% | 27 | $428.89 | |
| 95117 | <1% | 30 | $427.10 | |
| 90633 | <1% | 15,957 | $403.62 | |
| 74420 | <1% | 26 | $403.56 | |
| 88720 | <1% | 62 | $400.94 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 1,559 | $396.14 |
| 72052 | <1% | 13 | $394.98 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 401 | $391.54 |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | <1% | 14 | $382.59 |
| 82310 | <1% | 70 | $380.34 | |
| 83498 | <1% | 25 | $378.36 | |
| 85014 | <1% | 194 | $372.48 | |
| 93227 | <1% | 15 | $372.00 | |
| 90734 | <1% | 5,563 | $350.71 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 75 | $342.08 |
| 96377 | <1% | 18 | $319.90 | |
| 80164 | <1% | 20 | $314.40 | |
| 86304 | <1% | 15 | $314.08 | |
| J3490 | Unclassified drugs | <1% | 2,229 | $308.73 |
| 99407 | <1% | 14 | $307.32 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 45 | $300.20 |
| 82985 | <1% | 18 | $294.59 | |
| 93272 | <1% | 12 | $257.00 | |
| 82952 | <1% | 75 | $250.80 | |
| 36416 | <1% | 118 | $249.47 | |
| 96381 | <1% | 12 | $217.98 | |
| 90698 | <1% | 13,292 | $205.97 | |
| 86694 | <1% | 27 | $200.40 | |
| 94618 | <1% | 12 | $200.20 | |
| 80177 | <1% | 13 | $199.94 | |
| 82330 | <1% | 12 | $193.96 | |
| 81050 | <1% | 58 | $182.90 | |
| 82085 | <1% | 17 | $180.32 | |
| 90707 | <1% | 2,759 | $168.48 | |
| 87040 | <1% | 26 | $167.72 | |
| 93242 | <1% | 13 | $166.83 | |
| 98966 | <1% | 15 | $143.74 | |
| 94727 | <1% | 14 | $134.08 | |
| 90716 | <1% | 2,882 | $126.56 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 71 | $123.87 |
| 90680 | <1% | 21,014 | $109.93 | |
| 84155 | <1% | 39 | $102.24 | |
| S9083 | Global fee urgent care centers | <1% | 37,872 | $93.10 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 29 | $87.58 |
| 90744 | <1% | 5,640 | $65.36 | |
| 90723 | <1% | 10,654 | $63.99 | |
| 90647 | <1% | 7,027 | $63.52 | |
| 90710 | <1% | 3,158 | $62.80 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 49 | $43.55 |
| 90648 | <1% | 6,376 | $43.54 | |
| 90681 | <1% | 3,662 | $41.90 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 123 | $33.64 |
| 90700 | <1% | 764 | $26.48 | |
| 90380 | <1% | 35 | $25.75 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12 | $23.22 |
| 90696 | <1% | 1,808 | $21.56 | |
| 99412 | <1% | 192 | $17.29 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 43 | $16.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 14 | $2.17 |
| 90672 | <1% | 934 | $0.11 | |
| 3126F | <1% | 1,245 | $0.03 | |
| 0500F | 0% | 40,014 | $0.00 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 119 | $0.00 |
| 90677 | 0% | 37 | $0.00 | |
| 99429 | 0% | 36 | $0.00 | |
| 90381 | 0% | 62 | $0.00 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 0% | 332 | $0.00 |
| 85045 | 0% | 12 | $0.00 | |
| 0298T | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOLDERMAN, CLAY (COO/CDS)
| Provider | Location | Paid |
|---|---|---|
| Presbyterian Healthcare Services | Espanola, NM | $212K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.